• Royalty Pharma EVP, Research & Investments Marshall Urist sold 13,684 Class A Ordinary Shares on May 14, 2026.
• Sale priced at USD 53.06 per share on a weighted-average basis.
• Direct holdings fell to 31,881 Class A Ordinary Shares following transaction.
• Urist also reported 19,020 Class A Ordinary Shares held indirectly via an IRA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001838139-26-000016), on May 15, 2026, and is solely responsible for the information contained therein.